Jacc: Cardiooncology最新文献

{"title":"Mind the Translational Gap: Bidirectional Disease Associations Emphasize Need for Basic Science and Prospective Trials.","authors":"Caitlin Bell","doi":"10.1016/j.jaccao.2025.04.005","DOIUrl":"https://doi.org/10.1016/j.jaccao.2025.04.005","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":" ","pages":""},"PeriodicalIF":12.0,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144162949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of Hematologic Malignancies in Patients With Acute Myocardial Infarction: A Nationwide Population-Based Cohort Study.","authors":"Seug Yun Yoon, Mina Kim, Hoseob Kim, Duk Won Bang, Byoung-Won Park, Sun Young Jeong, Min-Young Lee, Kyoung Ha Kim, Namsu Lee, Jong-Ho Won, Inki Moon, Jon Suh, Seong Soon Kwon","doi":"10.1016/j.jaccao.2025.04.003","DOIUrl":"https://doi.org/10.1016/j.jaccao.2025.04.003","url":null,"abstract":"<p><strong>Background: </strong>Acute myocardial infarction (AMI) and cancer are leading causes of death worldwide. However, the relationship between AMI and hematologic malignancies remains unclear.</p><p><strong>Objectives: </strong>The authors aimed to investigate the association between AMI and the subsequent risk of incident hematologic malignancies.</p><p><strong>Methods: </strong>This retrospective cohort study included 103,686 patients with AMI and no history of hematologic malignancies, and 103,686 age- and sex-matched individuals with no history of AMI or hematologic malignancies, diagnosed between January 1, 2003, and December 31, 2021. Data were obtained from the Korean National Health Insurance claims database. We compared the cumulative incidence of hematologic malignancies between groups using Gray's method. HRs and 95% CIs were calculated using Gray's competing risk regression model, with death treated as a competing risk.</p><p><strong>Results: </strong>During follow-up (AMI, 7.9 years [Q1-Q3: 5.2-11.4 years]; control group, 17.8 years [Q1-Q3: 14.8-17.9 years]), 1,043 and 1,479 individuals in the AMI and control groups, respectively, were newly diagnosed with hematologic malignancies (incidence rate per 1,000 person-years: 1.21 vs 0.93). Competing risk analysis revealed that the AMI group had a higher risk of hematologic malignancy than the control group (HR: 1.49; 95% CI: 1.31-1.69). Findings were consistent in sensitivity and standardized incidence ratio analyses.</p><p><strong>Conclusions: </strong>Patients with AMI had a higher risk of hematologic malignancies than those without AMI. These findings suggest an association between AMI and hematologic malignancies, and underscore the importance of considering hematologic malignancy development in patients with AMI.</p>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":" ","pages":""},"PeriodicalIF":12.0,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144162953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mitigation of Doxorubicin Cardiotoxicity With Synergistic miRNA Combinations Identified Using Combinatorial Genetics en masse (CombiGEM).","authors":"Yasutomi Higashikuni, Colin Platt, Margaret H Hastings, William C W Chen, Justin R B Guerra, Takeshi Tokuyama, Fuad Gandhi Torizal, Wenhao Liu, Takumi Obana, Abraham L Bayer, Hannah Whipple, Alexandra Kuznetsov, Ashish Yeri, Cole Turissini, Robert R Kitchen, Kota Shibayama, Takayoshi Matsumura, Norihiko Takeda, Hideki Uosaki, Aarti H Asnani, Timothy K Lu, Anthony Rosenzweig","doi":"10.1016/j.jaccao.2025.03.007","DOIUrl":"https://doi.org/10.1016/j.jaccao.2025.03.007","url":null,"abstract":"<p><strong>Background: </strong>Cardiomyocyte loss occurs in acute and chronic cardiac injury, including cardiotoxicity due to chemotherapeutics like doxorubicin, and contributes to heart failure development. There is a pressing need for cardiac-specific therapeutics that target cardiomyocyte loss, preventing chemotherapy complications without compromising chemotherapeutic efficacy.</p><p><strong>Objectives: </strong>The authors employed massively parallel combinatorial genetic screening to find microRNA (miRNA) combinations that promote cardiomyocyte survival.</p><p><strong>Methods: </strong>CombiGEM (combinatorial genetics en masse) screening in a cardiomyocyte cell line was followed by validation in the original cell type and screening in primary cardiomyocytes. The top combination was tested in mouse and developing zebrafish models of doxorubicin cardiotoxicity. RNA sequencing provided insight into possible mechanisms.</p><p><strong>Results: </strong>Multiple miRNA combinations protected cardiomyocytes from doxorubicin in vitro. The most effective (miR-222+miR-455) appeared to act synergistically, and mitigated doxorubicin cardiotoxicity phenotypes in murine and zebrafish in vivo models. RNA sequencing revealed overlapping and synergistic regulation of relevant genes and biological processes in cardiomyocytes, including mitochondrial homeostasis, oxidative stress, muscle contraction, and others.</p><p><strong>Conclusions: </strong>We identified miR-222 and miR-455 as a combination with potential therapeutic applications for cardioprotection. This study furthers our knowledge of the cardiac effects of miRNAs and their combinations and demonstrates the potential of CombiGEM for cardioprotective combinatorial therapeutic discovery.</p>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":" ","pages":""},"PeriodicalIF":12.0,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144042417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation of Natriuretic Peptides with Invasively Measured Intracardiac Filling Pressures in Patients With Cancer.","authors":"Mariya M Fatakdawala, Hyeon-Ju Ryoo Ali, Juhee Song, Jorge A Irizarry-Caro, Saadia A Faiz, Salil Kumar, Syed Wamique Yusuf, Jean-Bernard Durand, Cezar Iliescu, Nicolas Palaskas, Anita Deswal, Efstratios Koutroumpakis","doi":"10.1016/j.jaccao.2025.03.006","DOIUrl":"https://doi.org/10.1016/j.jaccao.2025.03.006","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":" ","pages":""},"PeriodicalIF":12.0,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144046669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blood Pressure Lowering and Risk of Cancer: Individual Participant-Level Data Meta-Analysis and Mendelian Randomization Studies.","authors":"Milad Nazarzadeh, Emma Copland, Karl Smith Byrne, Dexter Canoy, Zeinab Bidel, Mark Woodward, Qianqian Yang, James McKay, Anders Mälarstig, Åsa K Hedman, John Chalmers, Koon K Teo, Carl J Pepine, Barry R Davis, Sverre E Kjeldsen, Johan Sundström, Kazem Rahimi","doi":"10.1016/j.jaccao.2025.03.005","DOIUrl":"https://doi.org/10.1016/j.jaccao.2025.03.005","url":null,"abstract":"<p><strong>Background: </strong>Pharmacologic blood pressure (BP) lowering is typically a lifelong treatment, and both clinicians and patients may have concerns about the long-term use of antihypertensive agents and the risk for cancer. However, evidence from randomized controlled trials (RCTs) regarding the effect of long-term pharmacologic BP lowering on the risk for new-onset cancer is limited, with most knowledge derived from observational studies.</p><p><strong>Objectives: </strong>The aim of this study was to assess whether long-term BP lowering affects the risk for new-onset cancer, cause-specific cancer death, and selected site-specific cancers.</p><p><strong>Methods: </strong>Individual-level data from 42 RCTs were pooled using a one-stage individual participant data meta-analysis. The primary outcome was incident cancer of all types, and secondary outcomes were cause-specific cancer death and selected site-specific cancers. Prespecified subgroup analyses were conducted to assess the heterogeneity of the BP-lowering effect by baseline variables and over follow-up time. Cox proportional hazards regression, stratified by trial, was used for the statistical analysis. For site-specific cancers, analyses were complemented with Mendelian randomization, using naturally randomized genetic variants associated with BP lowering to mimic the design of a long-term RCT.</p><p><strong>Results: </strong>Data from 314,016 randomly allocated participants without known cancer at baseline were analyzed. Over a median follow-up of 4 years (Q1-Q3: 3-5 years), 17,954 participants (5.7%) developed cancer, and 4,878 (1.5%) died of cancer. In the individual participant data meta-analysis, no associations were found between reductions in systolic or diastolic BP and cancer risk (HR per 5 mm Hg reduction in systolic BP: 1.03 [95% CI: 0.99-1.06]; HR per 3 mm Hg reduction in diastolic BP: 1.03 [95% CI: 0.98-1.07]). No changes in relative risk for incident cancer were observed over follow-up time, nor was there evidence of heterogeneity in treatment effects across baseline subgroups. No effect on cause-specific cancer death was found. For site-specific cancers, no evidence of an effect was observed, except a possible link with lung cancer risk (HR for systolic BP reduction: 1.17; 99.5% CI: 1.02-1.32). Mendelian randomization studies showed no association between systolic or diastolic BP reduction and site-specific cancers, including overall lung cancer and its subtypes.</p><p><strong>Conclusions: </strong>Randomized data analysis provided no evidence to indicate that pharmacologic BP lowering has a substantial impact, either increasing or decreasing, on the risk for incident cancer, cause-specific cancer death, or selected site-specific cancers.</p>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":" ","pages":""},"PeriodicalIF":12.0,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144057388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expanding Perspectives on Physical Activity and Cardiovascular Risk in Cancer Survivors","authors":"Fan Zhang MD,&nbsp;Wenlong Yu MD,&nbsp;Mengchen Yin PhD","doi":"10.1016/j.jaccao.2025.01.013","DOIUrl":"10.1016/j.jaccao.2025.01.013","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 3","pages":"Page 320"},"PeriodicalIF":12.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143833174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality-of-Care Measures for Cardio-Oncology","authors":"Vijay U. Rao MD, PhD ,&nbsp;Anita Deswal MD, MPH ,&nbsp;Daniel Lenihan MD ,&nbsp;Susan Dent MD ,&nbsp;Teresa Lopez-Fernandez MD ,&nbsp;Alexander R. Lyon MD ,&nbsp;Ana Barac MD, PhD ,&nbsp;Nicolas Palaskas MD ,&nbsp;Ming Hui Chen MD, MMSc ,&nbsp;Hector R. Villarraga MD ,&nbsp;Diego Sadler MD ,&nbsp;Courtney M. Campbell MD, PhD ,&nbsp;Kerry Skurka RN, BSN ,&nbsp;Matt J. Wagner ,&nbsp;Matthias Totzeck MD, PhD ,&nbsp;Kathryn J. Ruddy MD, MPH ,&nbsp;Paul Heidenreich MD ,&nbsp;Randal Thomas MD ,&nbsp;Daniel Addison MD ,&nbsp;Sarju Ganatra MD ,&nbsp;Joerg Herrmann MD","doi":"10.1016/j.jaccao.2024.11.003","DOIUrl":"10.1016/j.jaccao.2024.11.003","url":null,"abstract":"<div><div>This document serves as a perspective on quality assessments in the discipline of cardio-oncology. We aim to define the current landscape, identify needs for quality and outcome improvements, and propose a roadmap for establishing viable metrics to improve patient care. Specifically, this document: 1) addresses the current lack of measurable high-quality metrics in cardio-oncology and their implications; 2) highlights needs and topic-specific barriers; 3) illustrates the process and application of a measurable quality metric; and 4) provides a framework to demonstrate measurable value for the growing population of patients with cancer and cardiovascular diseases.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 3","pages":"Pages 191-202"},"PeriodicalIF":12.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143834992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intermuscular Fat and Physical Activity Levels Relative to Exercise Capacity Change During Breast Cancer Treatment","authors":"Lauren Daniel BS ,&nbsp;Moriah P. Bellissimo PhD ,&nbsp;Ralph B. D’Agostino Jr. PhD ,&nbsp;Kristine C. Olson PhD ,&nbsp;Amy C. Ladd PhD ,&nbsp;Kerryn W. Reding PhD ,&nbsp;Kathryn E. Weaver PhD ,&nbsp;Glenn J. Lesser MD ,&nbsp;Bonnie Ky MD, MSCE ,&nbsp;W. Gregory Hundley MD ,&nbsp;UPBEAT Study Team","doi":"10.1016/j.jaccao.2025.01.009","DOIUrl":"10.1016/j.jaccao.2025.01.009","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 3","pages":"Pages 297-299"},"PeriodicalIF":12.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143835003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reassessing CAC Risk Post-RRSO","authors":"Binglin Li MD,&nbsp;Yan Wang MD,&nbsp;Ruijuan Chen MD","doi":"10.1016/j.jaccao.2024.12.008","DOIUrl":"10.1016/j.jaccao.2024.12.008","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 3","pages":"Page 312"},"PeriodicalIF":12.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143834870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Balancing Promise and Evidence","authors":"Paschalis Karakasis MD, PhD(c) ,&nbsp;Dimitrios Patoulias MD, PhD ,&nbsp;Nikolaos Fragakis MD, PhD","doi":"10.1016/j.jaccao.2025.01.017","DOIUrl":"10.1016/j.jaccao.2025.01.017","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 3","pages":"Pages 314-315"},"PeriodicalIF":12.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143834986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}